Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 20/20 | 1.00 |
| ▸ | LOX | P28300 | 12/20 | 1.00 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL463199 | 0.98 | LOXL2 (0.96) | LOXL2LOXLOXL3 | |
| SCHEMBL6218599 | 0.85 | LOXL2 (0.73) | LOXL2LOX | |
| Trifluoroacetic Acid SCHEMBL16761282 | 0.84 | LOXL2 (0.71) | LOXL2LOX | |
| Hydrochloric Acid SCHEMBL2022971 | 0.83 | LOXL2 (0.71) | LOXL2LOX | |
| Hydrochloric Acid SCHEMBL12802921 | 0.83 | LOXL2 (0.71) | LOXL2LOX | |
| SCHEMBL4933505 | 0.82 | LOXL2 (0.70) | LOXL2LOXLOXL3 | |
| SCHEMBL21591576 | 0.82 | LOXL2 (0.69) | LOXL2LOX | |
| SCHEMBL805488 | 0.82 | LOXL2 (0.69) | LOXL2LOX | |
| SCHEMBL4379060 | 0.81 | LOXL2 (0.68) | LOXL2LOX | |
| SCHEMBL22336235 | 0.81 | LOXL2 (0.68) | LOXL2LOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 388 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3077380-B1 | THIENOMETHYLPIPERAZINE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | SANOFI SA (FR) | 2018-07-25 | — | — | EP | claimed |
| US-9776991-B2 | Thienomethylpiperazine derivatives as inhibitors of soluble epoxide hydrolase | SANOFI (FR) | 2017-10-03 | — | — | US | claimed |
| US-20160326146-A1 | THIENOMETHYLPIPERAZINE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | SANOFI (FR) | 2016-11-10 | — | — | US | claimed |
| EP-3077380-A1 | THIENOMETHYLPIPERAZINE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | Sanofi (FR) | 2016-10-12 | — | — | EP | claimed |
| WO-2015082474-A1 | THIENOMETHYLPIPERAZINE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | SANOFI (FR) | 2015-06-11 | — | — | WO | claimed |
| EP-2881390-A1 | Thienomethylpiperazine derivatives as inhibitors of soluble epoxide hydrolase | SANOFI (FR) | 2015-06-10 | — | — | EP | claimed |
| US-6949651-B2 | Fused bicyclic metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-09-27 | — | — | US | claimed |
| US-6897223-B2 | Pyridine fused bicyclic metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-05-24 | — | — | US | claimed |
| EP-1530472-A1 | ISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-05-18 | — | — | EP | claimed |
| EP-1492775-A2 | OXO-AZABICYCLIC COMPOUNDS | Warner-Lambert Company LLC (US) | 2005-01-05 | — | — | EP | claimed |
| EP-1362054-A1 | BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | claimed |
| WO-2003076417-A2 | OXO-AZABICYCLIC COMPOUNDS | WARNER-LAMBERT COMPANY LLC (US) | 2003-09-18 | — | — | WO | claimed |
| WO-2003076416-A1 | OXO AZABICYCLIC COMPOUNDS | WARNER-LAMBERT COMPANY LLC (US) | 2003-09-18 | — | — | WO | claimed |
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | HARTER WILLIAM GLEN (US) | 2003-01-02 | — | — | US | claimed |
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | ANDRIANJARA CHARLES (FR) | 2002-12-19 | — | — | US | claimed |
| US-20020156069-A1 | Benzo thiadiazine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY | 2002-10-24 | — | — | US | claimed |
| WO-2002064572-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | claimed |
| WO-2002064599-A1 | BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | claimed |
| WO-2002064598-A1 | THIENO'2,3-D PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | claimed |
| WO-2002064578-A1 | BENZO THIADIAZINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | MMP13, MMP3, MMP25 | LOXL2 794/4885LOX 247/4885LOXL3 474/4885 |
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | MMP13, MMP9, MMP3 | LOXL2 684/4885LOX 68/4885LOXL3 281/4885 |
| US-20020156069-A1 | Benzo thiadiazine matrix metalloproteinase inhibitors | MMP15, MMP13, MMP3 | LOXL2 950/4885LOX 597/4885LOXL3 1096/4885 |
| US-20160326146-A1 | THIENOMETHYLPIPERAZINE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | EPHX1, EPHX2, LTA4H | LOXL2 154/4885LOX 90/4885LOXL3 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.